BIIB

Biogen Inc operates with notably defensive characteristics for a biotechnology company, evidenced by its beta of 0.16—substantially below the market's 1.0 baseline. This low volatility profile combines with a market capitalization of $28.5 billion to position BIIB as a mature biotech operator rather than a growth-stage pharmaceutical developer. The company's valuation metrics reflect this transition, with a P/E ratio of 20.76 trading below typical high-growth biotech multiples, while the P/S ratio of 2.87 indicates compressed revenue multiples relative to innovation-focused competitors.

Profitability characteristics demonstrate established operational infrastructure. The gross margin of 75.49% confirms pricing power in marketed therapies, though the compression to a 17.47% operating margin reflects significant R&D and commercial infrastructure costs typical of CNS-focused biopharmaceuticals. Return metrics remain modest, with ROE at 7.54% and ROA at 4.71%, suggesting capital intensity challenges in sustaining the current product portfolio.

Fundamental screening highlights several risk factors:

• Revenue growth of 1.23% YoY indicates portfolio maturation pressures, likely reflecting biosimilar competition to legacy franchises
• EPS contraction of -8.05% YoY signals margin compression outpacing top-line stability
• Book value per share of $124.45 trading at a 1.41x multiple reflects moderate balance sheet premium

The conservative debt-to-equity ratio of 0.34 and current ratio of 2.68 provide financial flexibility for pipeline development or strategic transactions. Relative to peers VRTX and REGN, systematic models flag BIIB's defensive beta and mature valuation profile as distinct from higher-growth biotech characteristics typical in the sector.